» Articles » PMID: 2369816

In Vitro Studies of Ciprofloxacin and Survey of Resistance Patterns in Current Isolates

Overview
Date 1990 Mar 1
PMID 2369816
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the activity of ciprofloxacin and other antibiotics against both routine and multiresistant (multi-R) clinical isolates. Ciprofloxacin inhibited more than 98% of most species of Enterobacteriaceae at a concentration of 2 micrograms/ml. Only Acinetobacter calcoaceticus, and to a much lesser degree, Providencia and Serratia, were resistant. Most Pseudomonas aeruginosa isolates were susceptible. Only 1% of staphylococci were resistant; the test panel included 1200 MRSA. For most species of streptococci, the MIC90 was 1 microgram/ml; for enterococci, it was 2 micrograms/ml. We also surveyed resistance in our current isolates. Resistance to ciprofloxacin has increased in A. calcoaceticus and Providencia, and in Streptococcus pneumoniae and group B streptococci. Ciprofloxacin-resistant isolates tended to show increased resistance to other antibiotics, including aminoglycosides and, later, cephalosporins.

Citing Articles

Fluoroquinolone Therapy in Staphylococcus aureus Infections: Where Do We Stand?.

Gade N, Qazi M J Lab Physicians. 2014; 5(2):109-12.

PMID: 24701103 PMC: 3968619. DOI: 10.4103/0974-2727.119862.


High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Janoir C, Zeller V, Kitzis M, Moreau N, Gutmann L Antimicrob Agents Chemother. 1996; 40(12):2760-4.

PMID: 9124836 PMC: 163617. DOI: 10.1128/AAC.40.12.2760.


Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group.

Fuchs P, Barry A, Brown S J Clin Microbiol. 1997; 35(1):125-31.

PMID: 8968893 PMC: 229524. DOI: 10.1128/jcm.35.1.125-131.1997.


Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Davis R, Markham A, Balfour J Drugs. 1996; 51(6):1019-74.

PMID: 8736621 DOI: 10.2165/00003495-199651060-00010.


Penetration of ciprofloxacin into the human pancreas.

Isenmann R, Friess H, Schlegel P, Fleischer K, Buchler M Infection. 1994; 22(5):343-6.

PMID: 7843813 DOI: 10.1007/BF01715543.